Quick Answer
Editas Medicine, Inc. reported Long-Term Debt of $53.60 million for fiscal year 2025.
Editas Medicine, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $53.60M | +2.2% |
| 2024 | $52.43M | — |
| 2023 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $54.07M | — | +4.6% |
| June 30, 2025 | $51.67M | — | +4.2% |
| March 31, 2025 | $49.58M | — | -5.4% |
| December 31, 2024 | $52.43M | — | — |
- Editas Medicine, Inc. showed an increase of +2.2% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from Editas Medicine, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: